Search
192 matches for “ocrelizumab”
Trials (107)
- COAST: A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST)
- RAM-MS: Randomized study with stem cell transplantation versus standard treatment with alemtuzumab, cladribine or ocrelizumab in patients with relapsing remitting multiple sclerosis.
- StarMS: Stem cell transplantation versus disease modifying therapy (alemtuzumab or ocrelizumab) for patients with highly active relapsing remitting MS
- SIMSON trial: Research on the effect of add-on high dosage simvastatin treatment on progression in MS patients treated with ocrelizumab and natalizumab.
- OVERLORD-MS: Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease
Medicines (1)
Hypotheses (22)
- B-cell depletion (anti-CD20): prevent or delay MS in early MS (CIS or RIS)
- B-cell depletion (anti-CD20): protect nerve tissue in relapsing MS
- B-cell depletion (anti-CD20): protect nerve tissue in relapsing and progressive MS
- B-cell depletion (anti-CD20): slow disability worsening in primary progressive MS
- B-cell depletion (anti-CD20): slow disability worsening in relapsing MS
Papers (62)
- Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. ↗
- Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. ↗
- Ocrelizumab for multiple sclerosis. ↗
- Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review. ↗
- Real-World Persistence with Ocrelizumab in Multiple Sclerosis: a Systematic Review. ↗
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error